Get startedLog in
    Picture of Carisma Therapeutics logo

    CARM — Carisma Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    All News

    Brief: Sesen Bio Announces Strategic Decision To Pause Clinical Development Of Vicineum™ In The Us

    Picture of Carisma Therapeutics logoCarisma Therapeutics
    18/07/2022 14:16
    July 18 (Reuters) - Sesen Bio Inc  SESN.O :
    * SESEN BIO ANNOUNCES STRATEGIC DECISION TO PAUSE CLINICAL
DEVELOPMENT OF VICINEUM™ IN THE US
    * SESEN BIO INC - SESEN BIO CONTINUES TO FOCUS ON ASSESSMENT
OF
POTENTIAL STRATEGIC ALTERNATIVES
    * SESEN BIO INC - COMPANY INTENDS TO SEEK A PARTNER FOR
FURTHER
DEVELOPMENT OF VICINEUM
    * SESEN BIO INC - COMPANY INTENDS TO SEEK A PARTNER FOR
FURTHER
DEVELOPMENT OF VICINEUM
    * SESEN BIO INC - AS OF JUNE 30, 2022, COMPANY HAD $161.2
MILLION
IN CASH AND CASH EQUIVALENTS

Source text for Eikon:  ID:nBw6H3f1Ra 
Further company coverage:  SESN.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Carisma Therapeutics

    See all news